PURPOSE: To preserve photoreceptor cell structure and function in a rodent model of retinitis pigmentosa with P23H rhodopsin by selective inhibition of the mutant rhodopsin allele using a second generation antisense oligonucleotide (ASO). METHODS: Wild-type mice and rats were treated with ASO by intravitreal (IVT) injection and rhodopsin mRNA and protein expression were measured. Transgenic rats expressing the murine P23H rhodopsin gene (P23H transgenic rat Line 1) were administered either a mouse-specific P23H ASO or a control ASO. The contralateral eye was injected with PBS and used as a comparator control. Electroretinography (ERG) measurements and analyses of the retinal outer nuclear layer were conducted and correlated with rhodopsin mRNA levels. RESULTS: Rhodopsin mRNA and protein expression was reduced after a single ASO injection in wild-type mice with a rhodopsin-specific ASO. Transgenic rat eyes that express a murine P23H rhodopsin gene injected with a murine P23H ASO had a 181 ± 39% better maximum amplitude response (scotopic a-wave) as compared with contralateral PBS-injected eyes; the response in control ASO eyes was not significantly different from comparator contralateral eyes. Morphometric analysis of the outer nuclear layer showed a significantly thicker nuclear layer in eyes injected with murine P23H ASO (18%) versus contralateral PBS-injected eyes. CONCLUSIONS: Allele-specific ASO-mediated knockdown of mutant P23H rhodopsin expression slowed the rate of photoreceptor degeneration and preserved the function of photoreceptor cells in eyes of the P23H rhodopsin transgenic rat. Our data indicate that ASO treatment is a potentially effective therapy for the treatment of retinitis pigmentosa.
PURPOSE: To preserve photoreceptor cell structure and function in a rodent model of retinitis pigmentosa with P23Hrhodopsin by selective inhibition of the mutant rhodopsin allele using a second generation antisense oligonucleotide (ASO). METHODS: Wild-type mice and rats were treated with ASO by intravitreal (IVT) injection and rhodopsin mRNA and protein expression were measured. Transgenic rats expressing the murineP23Hrhodopsin gene (P23H transgenic rat Line 1) were administered either a mouse-specific P23HASO or a control ASO. The contralateral eye was injected with PBS and used as a comparator control. Electroretinography (ERG) measurements and analyses of the retinal outer nuclear layer were conducted and correlated with rhodopsin mRNA levels. RESULTS:Rhodopsin mRNA and protein expression was reduced after a single ASO injection in wild-type mice with a rhodopsin-specific ASO. Transgenic rat eyes that express a murineP23Hrhodopsin gene injected with a murineP23HASO had a 181 ± 39% better maximum amplitude response (scotopic a-wave) as compared with contralateral PBS-injected eyes; the response in control ASO eyes was not significantly different from comparator contralateral eyes. Morphometric analysis of the outer nuclear layer showed a significantly thicker nuclear layer in eyes injected with murineP23HASO (18%) versus contralateral PBS-injected eyes. CONCLUSIONS: Allele-specific ASO-mediated knockdown of mutant P23Hrhodopsin expression slowed the rate of photoreceptor degeneration and preserved the function of photoreceptor cells in eyes of the P23Hrhodopsin transgenic rat. Our data indicate that ASO treatment is a potentially effective therapy for the treatment of retinitis pigmentosa.
Authors: Donald Lee; Scott Geller; Natalie Walsh; Krisztina Valter; Doug Yasumura; Michael Matthes; Matthew LaVail; Jonathan Stone Journal: Adv Exp Med Biol Date: 2003 Impact factor: 2.622
Authors: Naomi Chadderton; Sophia Millington-Ward; Arpad Palfi; Mary O'Reilly; Gearóid Tuohy; Marian M Humphries; Tiansen Li; Peter Humphries; Paul F Kenna; G Jane Farrar Journal: Mol Ther Date: 2009-01-27 Impact factor: 11.454
Authors: T P Dryja; T L McGee; E Reichel; L B Hahn; G S Cowley; D W Yandell; M A Sandberg; E L Berson Journal: Nature Date: 1990-01-25 Impact factor: 49.962
Authors: S Machida; M Kondo; J A Jamison; N W Khan; L T Kononen; T Sugawara; R A Bush; P A Sieving Journal: Invest Ophthalmol Vis Sci Date: 2000-09 Impact factor: 4.799
Authors: Alejandro Garanto; Daniel C Chung; Lonneke Duijkers; Julio C Corral-Serrano; Muriël Messchaert; Ru Xiao; Jean Bennett; Luk H Vandenberghe; Rob W J Collin Journal: Hum Mol Genet Date: 2016-04-22 Impact factor: 6.150
Authors: Matthew M LaVail; Shimpei Nishikawa; Roy H Steinberg; Muna I Naash; Jacque L Duncan; Nikolaus Trautmann; Michael T Matthes; Douglas Yasumura; Cathy Lau-Villacorta; Jeannie Chen; Ward M Peterson; Haidong Yang; John G Flannery Journal: Exp Eye Res Date: 2017-11-06 Impact factor: 3.467
Authors: Silvia Albert; Alejandro Garanto; Riccardo Sangermano; Mubeen Khan; Nathalie M Bax; Carel B Hoyng; Jana Zernant; Winston Lee; Rando Allikmets; Rob W J Collin; Frans P M Cremers Journal: Am J Hum Genet Date: 2018-03-08 Impact factor: 11.025
Authors: Artur V Cideciyan; Raghavi Sudharsan; Valérie L Dufour; Michael T Massengill; Simone Iwabe; Malgorzata Swider; Brianna Lisi; Alexander Sumaroka; Luis Felipe Marinho; Tatyana Appelbaum; Brian Rossmiller; William W Hauswirth; Samuel G Jacobson; Alfred S Lewin; Gustavo D Aguirre; William A Beltran Journal: Proc Natl Acad Sci U S A Date: 2018-08-20 Impact factor: 11.205
Authors: Chenchen Niu; Thazah P Prakash; Aneeza Kim; John L Quach; Laryssa A Huryn; Yuechen Yang; Edith Lopez; Ali Jazayeri; Gene Hung; Bryce L Sopher; Brian P Brooks; Eric E Swayze; C Frank Bennett; Albert R La Spada Journal: Sci Transl Med Date: 2018-10-31 Impact factor: 17.956
Authors: Ratnesh K Singh; Francois Binette; Magdalene Seiler; Simon M Petersen-Jones; Igor O Nasonkin Journal: J Ocul Pharmacol Ther Date: 2020-10-14 Impact factor: 2.671